FDA warned telehealth seller Joi + Blokes that its website misbrands compounded semaglutide and tirzepatide with false, misleading claims.
What happened
FDA reviewed the company's website, joiandblokes.com, in March 2026 and found it offering compounded semaglutide and tirzepatide drug products. The agency said the pictured labels name "Joi + Blokes" as if the firm were the compounder, which it is not, and that the site calls its semaglutide "bioidentical" to and a cost-effective alternative to Ozempic and Wegovy. FDA said those statements falsely suggest the compounded products are FDA-approved or otherwise evaluated for safety and effectiveness.
What FDA found
The product labels shown on the website name Joi + Blokes as the maker, implying the firm compounds the drugs when it does not.
FD&C Act section 502(a) [21 U.S.C. § 352(a)]; 21 C.F.R. § 201.1(h)(2)The website says its compounded semaglutide uses the same "bioidentical compound" as Ozempic and Wegovy and is a cost-effective alternative, which suggests the compounded drug is FDA-approved when it is not.
FD&C Act sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]Selling these misbranded drugs across state lines is a prohibited act.
FD&C Act section 301(a) [21 U.S.C. § 331(a)]The firm has not shown its compounded drugs meet the conditions for exemption from new drug approval requirements.
FD&C Act sections 503A and 503B [21 U.S.C. §§ 353a, 353b]
What FDA wants
Within 15 business days, the company must send the Office of Compounding Quality and Compliance a written response in the email with steps taken and preventive measures. It must identify who actually makes the compounded drugs, supply sample labeling, and either fix or remove the misleading website claims.
Who should pay attention
- telehealth and online platforms selling compounded GLP-1 drugs
- compounders whose products are resold or white-labeled by marketers
- marketers and website operators advertising compounded drugs
This is a summary. Read the original letter on fda.gov.